Blood Coagulation Factors
- Name
- Blood Coagulation Factors
- Accession Number
- DBCAT000075 (DBCAT003566)
- Description
Endogenous substances, usually proteins, that promote the formation of blood clots.
- ATC Classification
- Drugs
Drug Drug Description Coagulation factor VIIa Recombinant Human A form of recombinant human coagulation Factor VII used to treat hemophilia A and B. Von Willebrand factor human A blood clotting factor used to manage bleeding episodes in von Willebrand disease and hemophilia A. Coagulation factor X human A coagulation factor used to treat Factor X deficiency to control bleeding. Antihemophilic factor, human recombinant A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency. Antihemophilic factor human A Factor VIII replacement therapy used to treat hemophilia A. Trenonacog alfa Human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells. Calcium A mineral found in over-the-counter supplements or prescription formulations used for the treatment of specific medical conditions related to calcium deficiency. Platelet Activating Factor Not Available Turoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Fibrinogen human A hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Thrombin A coagulation factor used to stop bleeding during surgery. Prothrombin A coagulation factor used for emergency reversal of vitamin K antagonist therapy. Factor IX Complex (Human) A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy. Rusalatide acetate Chrysalin has been used in trials studying the treatment of Radius Fracture. Vatreptacog alfa Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors. Factor XIII (human) A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency. Coagulation factor VII human A coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia. Kallidinogenase Not Annotated Nonacog beta pegol A recombinant coagulation Factor IX derivative used to treat hemophilia B. Moroctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Coagulation Factor IX (Recombinant) A form of recombinant human coagulation Factor IX used to treat hemophilia B. Catridecacog A recombinant FXIII subunit‐A molecule evaluated for clotting factor replacement therapy in congenital FXIII deficiency. Susoctocog alfa A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A. Anti-inhibitor coagulant complex A medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B. Human thrombin A platelet activating factor used to treat minor bleeding. Beroctocog alfa Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in... Andexanet alfa A recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban. Coagulation Factor IX Human A coagulation factor used to treat hemophilia B or factor IX hemophilia. Thrombin alfa A platelet activating factor used to treat minor bleeding. Calcium cation Not Annotated Pantothenic acid A vitamin B5 found in various nutritional supplements. Formic acid Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and... Antihemophilic factor (recombinant), PEGylated For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... Damoctocog alfa pegol A recombinant Factor VIII used to treat hemophilia A to control bleeding, perioperative bleeding, and also for prophylaxis of bleeding. Emicizumab An antibody against Factor IXa and Factor X used to treat hemophilia A. Turoctocog alfa pegol Turoctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to... Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B. Albutrepenonacog alfa A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. Protein S human A medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy. Marzeptacog alfa (activated) Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia). Coagulation factor XIa Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency). Rurioctocog alfa pegol A pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A. Valoctocogene roxaparvovec An adeno-associated virus serotype 5 (AAV5)-based gene therapy containing a coagulation factor VIII complementary DNA used to treat severe hemophilia A. Efanesoctocog alfa A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A. BAX 335 BAX 335 is an adeno-associated virus vector 8 (AAV8)–based FIX gene therapy being investigated for the treatment of hemophilia B. Humate-P Not Annotated PF-05230907 PF-05230907 is a recombinant activated Factor X variant. - Drugs & Drug Targets